Literature DB >> 20663926

Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells.

Rekha Rao1, Srilatha Nalluri, Warren Fiskus, Ramesh Balusu, Atul Joshi, Uma Mudunuru, Kathleen M Buckley, Kelly Robbins, Celalettin Ustun, Gary W Reuther, Kapil N Bhalla.   

Abstract

Nerve growth factor (NGF) induces autophosphorylation and downstream progrowth and prosurvival signaling from the receptor tyrosine kinase TrkA. Overexpression or activating mutation of TrkA has been described in human acute myeloid leukemia cells. In the present study, we show the chaperone association of TrkA with heat shock protein 90 (hsp90) and the inhibitory effect of the hsp90 inhibitor, 17-DMAG, on TrkA levels and signaling in cultured and primary myeloid leukemia cells. Treatment with 17-DMAG disrupted the binding of TrkA with hsp90 and the cochaperone cdc37, resulting in polyubiquitylation, proteasomal degradation, and depletion of TrkA. Exposure to 17-DMAG inhibited NGF-induced p-TrkA, p-AKT, and p-ERK1/2 levels, as well as induced apoptosis of K562, 32D cells with ectopic expression of wild-type TrkA or the constitutively active mutant Delta TrkA, and of primary myeloid leukemia cells. Additionally, 17-DMAG treatment inhibited NGF-induced neurite formation in the rat pheochromocytoma PC-12 cells. Cotreatment with 17-DMAG and K-252a, an inhibitor of TrkA-mediated signaling, induced synergistic loss of viability of cultured and primary myeloid leukemia cells. These findings show that TrkA is an hsp90 client protein, and inhibition of hsp90 depletes TrkA and its progrowth and prosurvival signaling in myeloid leukemia cells. These findings also support further evaluation of the combined activity of an hsp90 inhibitor and TrkA antagonist against myeloid leukemia cells. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663926      PMCID: PMC3008427          DOI: 10.1158/1535-7163.MCT-10-0336

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  48 in total

1.  Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.

Authors:  C Schneider; L Sepp-Lorenzino; E Nimmesgern; O Ouerfelli; S Danishefsky; N Rosen; F U Hartl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

2.  Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes.

Authors:  M L Grimes; J Zhou; E C Beattie; E C Yuen; D E Hall; J S Valletta; K S Topp; J H LaVail; N W Bunnett; W C Mobley
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

3.  Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells.

Authors:  S Chevalier; V Praloran; C Smith; D MacGrogan; N Y Ip; G D Yancopoulos; P Brachet; A Pouplard; H Gascan
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

4.  K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity.

Authors:  M M Berg; D W Sternberg; L F Parada; M V Chao
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

5.  The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells.

Authors:  A R Farina; A Tacconelli; L Cappabianca; G Cea; A Chioda; A Romanelli; S Pensato; C Pedone; A Gulino; A R Mackay
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

6.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

Authors:  A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

7.  Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

Authors:  Prince George; Purva Bali; Pamela Cohen; Jianguo Tao; Fei Guo; Celia Sigua; Anasuya Vishvanath; Warren Fiskus; Anna Scuto; Srinivas Annavarapu; Lynn Moscinski; Kapil Bhalla
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

8.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

Authors:  L A Greene; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

9.  Persistent TrkA activity is necessary to maintain transcription in neuronally differentiated PC12 cells.

Authors:  Jay H Chang; Eric Mellon; N Carolyn Schanen; Jeffery L Twiss
Journal:  J Biol Chem       Date:  2003-08-08       Impact factor: 5.157

10.  K-252a, a potent protein kinase inhibitor, blocks nerve growth factor-induced neurite outgrowth and changes in the phosphorylation of proteins in PC12h cells.

Authors:  S Hashimoto
Journal:  J Cell Biol       Date:  1988-10       Impact factor: 10.539

View more
  7 in total

1.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Authors:  Ramesh Balusu; Warren Fiskus; Rekha Rao; Daniel G Chong; Srilatha Nalluri; Uma Mudunuru; Hongwei Ma; Lei Chen; Sreedhar Venkannagari; Kyungsoo Ha; Sunil Abhyankar; Casey Williams; Joseph McGuirk; Hanna Jean Khoury; Celalettin Ustun; Kapil N Bhalla
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

2.  Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.

Authors:  Daniel Brigger; Bruce E Torbett; Joy Chen; Martin F Fey; Mario P Tschan
Journal:  Biochem Biophys Res Commun       Date:  2013-07-24       Impact factor: 3.575

3.  1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1).

Authors:  Narsimha Reddy Penthala; Amit Ketkar; Konjeti R Sekhar; Michael L Freeman; Robert L Eoff; Ramesh Balusu; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2015-11-15       Impact factor: 3.641

4.  Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms.

Authors:  Alessandro Pecci; Vittorio Necchi; Serena Barozzi; Agostina Vitali; Emanuela Boveri; Chiara Elena; Paolo Bernasconi; Patrizia Noris; Enrico Solcia
Journal:  J Hematol Oncol       Date:  2015-06-18       Impact factor: 17.388

5.  TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.

Authors:  Wenyu Shi; Suraj Konnath George; Bhawana George; Choladda V Curry; Albina Murzabdillaeva; Serhan Alkan; Hesham M Amin
Journal:  Mol Oncol       Date:  2017-06-18       Impact factor: 6.603

6.  The structure-function relationship of oncogenic LMTK3.

Authors:  Angeliki Ditsiou; Chiara Cilibrasi; Nikiana Simigdala; Athanasios Papakyriakou; Leanne Milton-Harris; Viviana Vella; Joanne E Nettleship; Jae Ho Lo; Shivani Soni; Goar Smbatyan; Panagiota Ntavelou; Teresa Gagliano; Maria Chiara Iachini; Sahir Khurshid; Thomas Simon; Lihong Zhou; Storm Hassell-Hart; Philip Carter; Laurence H Pearl; Robin L Owen; Raymond J Owens; S Mark Roe; Naomi E Chayen; Heinz-Josef Lenz; John Spencer; Chrisostomos Prodromou; Apostolos Klinakis; Justin Stebbing; Georgios Giamas
Journal:  Sci Adv       Date:  2020-11-13       Impact factor: 14.136

Review 7.  Heat Shock Proteins Regulatory Role in Neurodevelopment.

Authors:  David J Miller; Patrice E Fort
Journal:  Front Neurosci       Date:  2018-11-12       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.